Loading clinical trials...
Loading clinical trials...
Multicenter, Open-label, Early Access Program of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Genotype 1 Chronic Hepatitis C Subjects With Severe Fibrosis and Compensated Cirrhosis
Conditions
Interventions
Telaprevir + peginterferon alfa + ribavirin
peginterferon alfa + ribavirin
+1 more
Locations
128
Australia
Adelaide, Australia
Bedford, Australia
Box Hill, Australia
Camperdown, Australia
Central Queensland M C, Australia
Concord, Australia
Last Updated
July 24, 2015
NCT06953479
NCT03135886
NCT05968573
NCT05042544
NCT05870969
NCT05361603
Lead Sponsor
Janssen-Cilag International NV
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions